Lineage Cell Therapeutics completes first cGMP batch of hearing loss cell therapy
LCTX•Lineage Cell Therapeutics completed the first clinical-grade cGMP batch of its ReSonance hearing-loss cell therapy and all planned first-year development activities. Its partner committed up to $12 million over three years beginning in August 2025.
1. First-year milestones complete
Lineage Cell Therapeutics said it completed all planned first-year development activities for ReSonance, advancing the hearing-loss cell therapy into the second year of its collaboration. Manufacturing produced the first clinical-grade cGMP batch and three engineering batches, completing the transfer from research to the cGMP team.
2. Testing and regulatory plans
Researchers established a deafening model for functional preclinical testing of the therapy, which targets auditory nerve degeneration. A meeting with the Danish Medicines Agency is planned for the fourth quarter of 2026 to review development plans and seek scientific advice. Partner William Demant Invest committed up to $12 million for collaboration research costs over three years beginning in August 2025.
